Anteris Technologies Global Corp. (AVR) - Dilution Analysis

10-Q filing | 97.3M shares outstanding

S-3 filing: This is an S-3 filing for a shelf offering of various securities, including common stock, preferred stock, depositary shares, warrants, subscription rights, contingent value rights, debt securities, and purchase contracts, with an aggregate initial offering price of $500,000,000.

S-1 filing: This S-1 filing relates to the offering of Common Stock by selling stockholders. The company will not receive any proceeds from the sale of these shares but may receive proceeds from the exercise of warrants.

10-Q filing | 41.2M shares outstanding

8-K filing: Anteris Technologies Global Corp. closed a common stock offering on October 27, 2025, issuing 2,346,936 shares and warrants, receiving approximately $11.5 million in gross proceeds. ($11.5M proceeds)

8-K filing: Anteris Technologies Global Corp. entered into subscription agreements to sell 2,244,896 shares of common stock and accompanying warrants at US$4.90 per share and confirmation letters to sell 2,788,064 CHESS Depositary Interests (CDIs) and accompanying warrants at A$7.50 per CDI, expecting aggregate gross proceeds of approximately US$25 million.

10-Q filing | 36.0M shares outstanding

8-K filing: The Company closed its IPO of 14,800,000 shares of its Common Stock, at a price to the public of $6.00 per share, with net proceeds to the Company of $80.0 million. ($80.0M proceeds)

S-1/A filing: This S-1/A filing details a common stock offering. 14,800,000 shares are offered, with underwriters having an option to purchase an additional 2,220,000 shares. Post-offering, 35,939,816 shares will be outstanding (or 38,159,816 if the underwriter option is fully exercised). The net proceeds are estimated at $90.6 million (or $104.5 million if the underwriter option is fully exercised), and will be used for the ongoing development of DurAVR® THV and the preparation and enrollment of the Pivotal Trial of DurAVR® THV for treating severe aortic stenosis, with the remaining for working capital and other general corporate purposes determined from time to time, including the repayment of amounts owed under the Convertible Note Facility.

S-1 filing: This S-1 filing outlines an initial public offering of common stock, with underwriters granted an option to purchase additional shares. The company intends to list its Common Stock on NASDAQ under the symbol "AVR" and expects its CDIs to commence trading on the ASX under the same symbol. The net proceeds will be used for the development of DurAVR® THV and related clinical trials, with the remainder for working capital and general corporate purposes.